1. Home
  2. WVE vs AVXL Comparison

WVE vs AVXL Comparison

Compare WVE & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • AVXL
  • Stock Information
  • Founded
  • WVE 2012
  • AVXL 2004
  • Country
  • WVE Singapore
  • AVXL United States
  • Employees
  • WVE N/A
  • AVXL N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WVE Health Care
  • AVXL Health Care
  • Exchange
  • WVE Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • WVE 915.6M
  • AVXL 794.0M
  • IPO Year
  • WVE 2015
  • AVXL N/A
  • Fundamental
  • Price
  • WVE $6.50
  • AVXL $9.28
  • Analyst Decision
  • WVE Strong Buy
  • AVXL Strong Buy
  • Analyst Count
  • WVE 13
  • AVXL 2
  • Target Price
  • WVE $20.15
  • AVXL $44.00
  • AVG Volume (30 Days)
  • WVE 1.0M
  • AVXL 894.6K
  • Earning Date
  • WVE 08-07-2025
  • AVXL 08-05-2025
  • Dividend Yield
  • WVE N/A
  • AVXL N/A
  • EPS Growth
  • WVE N/A
  • AVXL N/A
  • EPS
  • WVE N/A
  • AVXL N/A
  • Revenue
  • WVE $104,939,000.00
  • AVXL N/A
  • Revenue This Year
  • WVE N/A
  • AVXL N/A
  • Revenue Next Year
  • WVE $1.94
  • AVXL N/A
  • P/E Ratio
  • WVE N/A
  • AVXL N/A
  • Revenue Growth
  • WVE N/A
  • AVXL N/A
  • 52 Week Low
  • WVE $4.87
  • AVXL $4.00
  • 52 Week High
  • WVE $16.74
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • WVE 45.10
  • AVXL 65.76
  • Support Level
  • WVE $6.67
  • AVXL $9.10
  • Resistance Level
  • WVE $7.10
  • AVXL $9.80
  • Average True Range (ATR)
  • WVE 0.38
  • AVXL 0.42
  • MACD
  • WVE -0.02
  • AVXL 0.16
  • Stochastic Oscillator
  • WVE 7.77
  • AVXL 83.42

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: